Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

Novo Nordisk has licensed an oral obesity drug that works via an uncommon mechanism and may help patients maintain their ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.

Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity ...

Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to LX9851, an ...

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese ...

Novo Nordisk to Pay $2 Billion for New Weight Loss Drug TUESDAY, March 25, 2025 (HealthDay News) -- Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion ...

Novo Nordisk's hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after a series of trial results sent shares falling. Headline results from a ...

Novo Nordisk will pay as much as $2 billion for a new obesity drug called UBT251 The company now holds the exclusive rights to develop, manufacture and sell the drug in much of the world It has ...